Drug intelligence / Profile preview

acetylcysteine + ascorbic acid

Development stage
Unknown
Lead developer
Abian Pharmed
Modality
Small Molecules
Administration
Oral
01

Overview

Broncetyl-C is an oral combination of acetylcysteine (600 mg) and ascorbic acid (vitamin C, 75 mg) developed and marketed by Abian Pharmed. Acetylcysteine acts as a mucolytic agent by reducing disulfide bonds in mucoproteins, thereby thinning viscous mucus in the respiratory tract and facilitating its clearance. Ascorbic acid is included to enhance the antioxidant and therapeutic efficacy of acetylcysteine. Broncetyl-C is approved in Iran for the treatment of respiratory diseases characterized by excessive or thick mucus production, such as bronchitis, chronic asthma, pneumonia, and emphysema, and can also serve as an antidote for acetaminophen toxicity.

Brand names
Broncetyl-CLumenac-CMuconex-C
Other names
acetylcysteine + ascorbic acidacetylcysteine + vitamin C
02

Targets

TRPA1 (Transient receptor potential cation channel subfamily A member 1)SLC7A11 (Cystine-Glutamate Antiporter)2-OGDD (Fe(II)/2-oxoglutarate-dependent dioxygenase)

Beyond the preview

Go deeper on acetylcysteine + ascorbic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on acetylcysteine + ascorbic acid.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call